Danielle Brill
Stock Analyst at Raymond James
(3.48)
# 922
Out of 4,681 analysts
74
Total ratings
54.29%
Success rate
5.12%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $50.33 | +29.15% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $25.63 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $65.04 | +21.46% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $10.00 | +80.00% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $125.89 | +23.12% | 5 | Oct 10, 2024 | |
| QURE uniQure | Reinstates: Outperform | $20 | $7.13 | +180.50% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $28.79 | +25.04% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $35.13 | +13.86% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $127.95 | +17.23% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $164.23 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $5.79 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $465.73 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $617.49 | -2.02% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $16.61 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $42.12 | +18.71% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $58.87 | -13.37% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $64.22 | -33.04% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $1.01 | +395.05% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $52.07 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.42 | - | 5 | Jun 27, 2023 |
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $50.33
Upside: +29.15%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $25.63
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $65.04
Upside: +21.46%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $10.00
Upside: +80.00%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $125.89
Upside: +23.12%
uniQure
Oct 10, 2024
Reinstates: Outperform
Price Target: $20
Current: $7.13
Upside: +180.50%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $28.79
Upside: +25.04%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $35.13
Upside: +13.86%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $127.95
Upside: +17.23%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $164.23
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $5.79
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $465.73
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $617.49
Upside: -2.02%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $16.61
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $42.12
Upside: +18.71%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $58.87
Upside: -13.37%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $64.22
Upside: -33.04%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $1.01
Upside: +395.05%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $52.07
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.42
Upside: -